DE1809120A1 - Magnesium monoaspartate hydroiodicle useful - in treating thyroid ailments - Google Patents

Magnesium monoaspartate hydroiodicle useful - in treating thyroid ailments

Info

Publication number
DE1809120A1
DE1809120A1 DE19681809120 DE1809120A DE1809120A1 DE 1809120 A1 DE1809120 A1 DE 1809120A1 DE 19681809120 DE19681809120 DE 19681809120 DE 1809120 A DE1809120 A DE 1809120A DE 1809120 A1 DE1809120 A1 DE 1809120A1
Authority
DE
Germany
Prior art keywords
magnesium
monoaspartate
ailments
useful
hydroiodicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19681809120
Other languages
German (de)
Inventor
Dr Franz Fischer
Dr Joachim Helbig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VERLA PHARM
Original Assignee
VERLA PHARM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VERLA PHARM filed Critical VERLA PHARM
Priority to DE19681809120 priority Critical patent/DE1809120A1/en
Publication of DE1809120A1 publication Critical patent/DE1809120A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B64AIRCRAFT; AVIATION; COSMONAUTICS
    • B64FGROUND OR AIRCRAFT-CARRIER-DECK INSTALLATIONS SPECIALLY ADAPTED FOR USE IN CONNECTION WITH AIRCRAFT; DESIGNING, MANUFACTURING, ASSEMBLING, CLEANING, MAINTAINING OR REPAIRING AIRCRAFT, NOT OTHERWISE PROVIDED FOR; HANDLING, TRANSPORTING, TESTING OR INSPECTING AIRCRAFT COMPONENTS, NOT OTHERWISE PROVIDED FOR
    • B64F1/00Ground or aircraft-carrier-deck installations
    • B64F1/18Visual or acoustic landing aids
    • B64F1/20Arrangement of optical beacons

Abstract

Mg. monoaspartate hydroiodide is a new compound useful for treating thyroid ailments and is produced by adding hydriodic acid to magnesium diaspartate.

Description

Magnesiummonoaspartathydrojodid Die vorliegende Erfindung betrifft die neue Verbindung Magnesiummonoaspartathydrojodid der Formel Diese Verbindung besitzt in wasserfreiem Zustand ein Moleku largewicht von 283,34. Sie liegt im allgemeinen in einer kristallwasserhaltigen Form (3H2O) vor. Diese Verbindung ist farblos, mit gelblichem Stich, kristallin (glaskiare Platten). Der pH-Wert einer 1 %igen Lösung in Wasser beträgt 4,5 - 4,8. Die spezifische Drehung einer 6 %igen 1-n-HCl-Lösung beträgt +12,5 ; 2. Der Mischschmelzpunkt mit Dioyandiamid wird zu 188°C ermittelt. Die Löslichkeit in Wasser beträgt 1:5 (heiss). In Alkohol, Aceton und Chloroform ist die erfindungsgemässe Substanz schwer löslich.Magnesium monoaspartate hydroiodide The present invention relates to the novel compound magnesium monoaspartate hydroiodide of the formula This compound has a molecular weight of 283.34 in the anhydrous state. It is generally in a form containing water of crystallization (3H2O). This compound is colorless, with a yellowish tinge, crystalline (glassy plates). The pH of a 1% solution in water is 4.5-4.8. The specific rotation of a 6% 1 n HCl solution is +12.5; 2. The mixed melting point with dioyandiamide is found to be 188 ° C. The solubility in water is 1: 5 (hot). The substance according to the invention is sparingly soluble in alcohol, acetone and chloroform.

Das erfindungsgemässe Magnesiummonoaspartathydrojodid lässt sich aus Magnesiumdiaspartat durch Zugabe von Jodwasserstoffsäure nach folgendem Reaktionsschema herstellen: Die Jodwasserstoffsäure muß der Lösung des Magnesiumdiaspartats schnell zugesetzt werden, denn sobald Asparaginsäure ausfällt, bildet sich eine thixotrope Masse, welche sich nur schwer durchmischen läßt.The magnesium monoaspartate hydroiodide according to the invention can be produced from magnesium diaspartate by adding hydriodic acid according to the following reaction scheme: The hydriodic acid must be added quickly to the solution of the magnesium diaspartate, because as soon as aspartic acid precipitates, a thixotropic mass is formed which is difficult to mix.

Die Reaktion wird am zweckmäßigsten in einem wäßrigen Medium unter Verwendung der stöchiometrischen Mengen der Reaktanten durchgeführt. Die ausgefallene Asparaginsäure wird nach beendeter Umsetzung abfiltriert. Nach Einengen des Filtrats kristallisiert das erfindungsgemäße Magnesiummonoaspartathydrojodid aus. Die Verbindung kann nach üblichen Methoden, beispielsweise durch Umkristallisation, gereinigt werden.The reaction is most conveniently carried out in an aqueous medium Using the stoichiometric amounts of the reactants carried out. The unusual one Aspartic acid is filtered off after the reaction has ended. After concentrating the filtrate The magnesium monoaspartate hydroiodide according to the invention crystallizes out. The connection can be purified by customary methods, for example by recrystallization.

Das erfindungsgemäße Magnesiummonoaspartathydrojodid zeichnet sich in überraschender Weise durch eine sehr große Komplexstabilität aus. Diese Tatsache ist insofern besonders überraschend, als das entsprechende Magnesiumglutamathydrojodid eine wesentlich geringere Komplexstabilität besitzt. Daher eignet sich die erfindungsgemäße Verbindung in hervorragender Weise zur Magnesiumtherapie, da diese Verbindung aufgrund der geschilderten Eigenschaften die Gewähr für eine weitgehende Resorption und gute Organverteilung bietet.The magnesium monoaspartate hydroiodide according to the invention is distinguished in a surprising way by a very high complex stability. this fact is particularly surprising as the corresponding magnesium glutamate hydroiodide has a much lower complex stability. The invention is therefore suitable Connection in an excellent way to magnesium therapy, as this connection is due the properties described guarantee extensive and good absorption Organ distribution offers.

Insbesondere eignet sich Magnesiummonoaspartathydrojodid zur Behandlung von Schilddrüsenerkrankungen. Thyreotoxikosen wurden früher mit Jodverbindungen behandelt. Dabei traten jedoch Jod-Allergien auf, so daß etwas Zurückhaltung in der Behandlung von Schilddrüsenerkrankungen mit Jodverbindungen geübt wurde.Magnesium monoaspartate hydroiodide is particularly suitable for treatment of thyroid disease. Thyrotoxicoses were earlier with iodine compounds treated. However, there were iodine allergies, so there was some reluctance to do so the treatment of thyroid disorders with iodine compounds has been practiced.

Durch den pharmakologischen Effekt von Magnesium (sedierende Wirkung) kann man einmal Thyreotoxikosen mit Magnesiumverbindungen behandeln. In der letzten Zeit wurde andererseits festgestellt, daß enge Beziehungen zwischen der Schilddrüse und dem Magnesiumstoffwechsel bestehen. Bei Hyperthyreosen wurde eine erhöhte und bei Hypothyreosen eine verminderte Magnesiumausscheidung im Urin festgestellt. Daraus wurde der Schluß gezogen (vgl. Medizinische Welt, 18 N.F (1967) 3032), daß es bei Schilddrüsenerkrankungen zu einer Störung der Magnesiumbilanz kommen kann.Due to the pharmacological effect of magnesium (sedative effect) one can treat thyrotoxicosis with magnesium compounds. In the last Time, on the other hand, was found to have close relationships between the thyroid gland and the magnesium metabolism. In hyperthyroidism was increased and, in hypothyroidism, decreased magnesium excretion in the urine established. The conclusion was drawn from this (see Medical World, 18 N.F (1967) 3032) that thyroid disorders lead to a disruption of the magnesium balance can come.

Bei Verwendung des erfindungsgemäßen Magnesiummonoaspartathydrojodids zur Behandlung von Schilddrüsenerkrankungen wird die klassische Therapie der Schilddrtisenerkrankungen mit Jodverbindungen mit der modernen ßrkenntnis verbunden, daß Magnesium bei Schilddrüsenerkrankungen eine Rolle spielt. Außerdem ist die Gefahr einer Jodallergie vermindert.When using the magnesium monoaspartate hydroiodide according to the invention The classic therapy of thyroid diseases is used to treat thyroid diseases connected with iodine compounds with the modern knowledge that magnesium in thyroid diseases plays a role. In addition, the risk of an iodine allergy is reduced.

Claims (2)

PatentansprücheClaims 1. Magnesiummonoaspartathydrojodid.1. Magnesium monoaspartate hydroiodide. 2. Präparat zur Behandlung von Schilddrüsenerkrankungen, gekonnzeichnet durch einen Gehalt an Magnesiummonoaspartathydrojodid2. Preparation for the treatment of thyroid diseases, skilfully drawn by a content of magnesium monoaspartate hydroiodide
DE19681809120 1968-11-15 1968-11-15 Magnesium monoaspartate hydroiodicle useful - in treating thyroid ailments Pending DE1809120A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19681809120 DE1809120A1 (en) 1968-11-15 1968-11-15 Magnesium monoaspartate hydroiodicle useful - in treating thyroid ailments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19681809120 DE1809120A1 (en) 1968-11-15 1968-11-15 Magnesium monoaspartate hydroiodicle useful - in treating thyroid ailments

Publications (1)

Publication Number Publication Date
DE1809120A1 true DE1809120A1 (en) 1970-06-11

Family

ID=5713435

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19681809120 Pending DE1809120A1 (en) 1968-11-15 1968-11-15 Magnesium monoaspartate hydroiodicle useful - in treating thyroid ailments

Country Status (1)

Country Link
DE (1) DE1809120A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3238118A1 (en) * 1982-10-14 1984-04-19 Verla-Pharm, Arzneimittelfabrik Apotheker H.J. v. Ehrlich GmbH & Co KG, 8132 Tutzing METHOD FOR PRODUCING COMPLEX COMPOUNDS FROM AMINODICARBONIC ACIDS, DUAL VALUE METALIONS AND HALOGENIDIONS
CN106927014A (en) * 2017-03-14 2017-07-07 上海帆煜自动化科技有限公司 A kind of lightweight unmanned plane of high-strength corrosion-resisting

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3238118A1 (en) * 1982-10-14 1984-04-19 Verla-Pharm, Arzneimittelfabrik Apotheker H.J. v. Ehrlich GmbH & Co KG, 8132 Tutzing METHOD FOR PRODUCING COMPLEX COMPOUNDS FROM AMINODICARBONIC ACIDS, DUAL VALUE METALIONS AND HALOGENIDIONS
CN106927014A (en) * 2017-03-14 2017-07-07 上海帆煜自动化科技有限公司 A kind of lightweight unmanned plane of high-strength corrosion-resisting

Similar Documents

Publication Publication Date Title
DE2534391C2 (en) 1-Hydroxy-3-aminoalkane-1,1-diphosphonic acids
EP0001584B1 (en) Hydroxydiphosphonic acids, process for their preparation and their use as complex-forming agents
DE3709230A1 (en) NEW VALPROINIC ACID CALCIUM
DE2534390C2 (en) 1,3-di-aminoalkane-1,1-diphosphonic acids
DE1809120A1 (en) Magnesium monoaspartate hydroiodicle useful - in treating thyroid ailments
DE1809119A1 (en) Magnesium aspartate prepn for the treatment - of infarction conditions
DE2036935A1 (en) Process for the production of isoniazid derivatives
DE944953C (en) Process for the preparation of a therapeutic agent consisting of the calcium salt of Ca-ethylene diamine tetraacetic acid
DE1670378A1 (en) Process for the preparation of a compound from phenylbutazone and ss-diaethylaminoaethylamide of p-chlorophenoxyacetic acid
DE1147589B (en) Process for the preparation of bactericidally active derivatives of 1- (5-nitrofurfurylidene-amino) -hydantoin substituted in the 3-position
DE2745084A1 (en) 5-Keto-piperazine-2,2-di:phosphonic acid derivs. - useful as chelating agents e.g. in water treatment, for providing trace elements and treating metabolic disorders
DE2241076B2 (en) Tetracycline complex and its salts, process for its preparation and pharmaceutical compositions containing this complex
AT265243B (en) Process for the preparation of new salts of p-chlorophenoxyisobutyric acid
DE1809121A1 (en) Magnesium monoaspartate hydrobromide useful - as a sectative or tranquilliser
DE2317114C3 (en) Glycyrrhetinic acid derivatives and processes for their preparation
DE1468681C3 (en) 17beta-tetrahydropyranyloxy compounds of the androstane series as well as processes for their production and remedies
DE2318043C3 (en) Bis-square brackets on 4,7-dihydroxycumarinyl- (3) square brackets acetic acid and its pharmacologically acceptable salts as well as processes for their production and pharmaceuticals containing these compounds
DE760326C (en) Process for the preparation of diesters of oxy-ª ‡, ª ‰ -diaethyl-ª ‡, ª ‰ -diarylaethanes
DE1809118A1 (en) Mono magnesium aspartate hydrofluoride
DE1961527A1 (en) Crystalline form of citric anhydride
AT206590B (en) Process for the production of new derivatives of the lysergic acid series substituted on indole nitrogen
DE544667C (en) Process for the preparation of 2-oxy-3-aminopyridine-5-arsic acid
AT267053B (en) Process for the preparation of the new chloramphenicol succinic acid ester salt of pyrrolidinomethyl-tetracycline
CH239643A (en) Process for the preparation of an aqueous solution of a molecular compound of lactoflavin.
DEF0008821MA (en)

Legal Events

Date Code Title Description
SH Request for examination between 03.10.1968 and 22.04.1971